Your search returned 46 results.

Results
	1.	Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. [electronic resource] by Apuri, Susmitha Al Ali, Najla Padron, Eric Lancet, Jeffrey E List, Alan F Komrokji, Rami S Producer: 20171108 In: Clinical lymphoma, myeloma & leukemia vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. [electronic resource] by Zeidan, Amer M Al Ali, Najla H Padron, Eric Lancet, Jeffrey List, Alan Komrokji, Rami S Producer: 20160909 In: Clinical lymphoma, myeloma & leukemia vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. [electronic resource] by Haider, Mintallah Al Ali, Najla Padron, Eric Epling-Burnette, Pearlie Lancet, Jeffrey List, Alan Komrokji, Rami Producer: 20171103 In: Clinical lymphoma, myeloma & leukemia vol. 16 Suppl Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. [electronic resource] by Komrokji, Rami Ramadan, Hanadi Al Ali, Najla Corrales-Yepez, Maria Zhang, Ling Padron, Eric Lancet, Jeffrey List, Alan Producer: 20160613 In: Clinical lymphoma, myeloma & leukemia vol. 15 Suppl Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. [electronic resource] by Grabska, Joanna Shah, Bijal Reed, Damon Al Ali, Najla Padron, Eric Ramadan, Hanadi Lancet, Jeffrey List, Alan Komrokji, Rami Producer: 20171103 In: Clinical lymphoma, myeloma & leukemia vol. 16 Suppl Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. [electronic resource] by Komrokji, Rami S Al Ali, Najla H Padron, Eric Cogle, Christopher Tinsley, Sara Sallman, David Lancet, Jeffrey E Lis, Alan F Producer: 20200520 In: Clinical lymphoma, myeloma & leukemia vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. [electronic resource] by Duong, Vu H Al Ali, Najla Zhang, Ling Padron, Eric Sallman, David Lancet, Jeffrey E List, Alan F Komrokji, Rami S Producer: 20210427 In: Leukemia & lymphoma vol. 61 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. [electronic resource] by Ramadan, Hanadi Duong, Vu H Al Ali, Najla Padron, Eric Zhang, Ling Lancet, Jeffrey E List, Alan F Komrokji, Rami S Producer: 20171103 In: Clinical lymphoma, myeloma & leukemia vol. 16 Suppl Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. [electronic resource] by Komrokji, Rami S Corrales-Yepez, Maria Al Ali, Najla Kharfan-Dabaja, Mohammad Padron, Eric Fields, Teresa Lancet, Jeffrey E List, Alan F Producer: 20120621 In: Cancer vol. 118 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. [electronic resource] by Duong, Vu H Lin, Karen Reljic, Tea Kumar, Ambuj Al Ali, Najla H Lancet, Jeffrey E List, Alan F Komrokji, Rami S Producer: 20140718 In: Clinical lymphoma, myeloma & leukemia vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. [electronic resource] by Komrokji, Rami S Matacia-Murphy, Gina M Al Ali, Najla H Beg, M S Safa, Malek M Rollison, Dana E List, Alan F Producer: 20100218 In: Leukemia research vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. [electronic resource] by Migdady, Yazan Barnard, John Al Ali, Najla Steensma, David P DeZern, Amy Roboz, Gail Garcia-Manero, Guillermo Sekeres, Mikkael A Komrokji, Rami S Producer: 20191022 In: Clinical lymphoma, myeloma & leukemia vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	13.	SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. [electronic resource] by Zhang, Qing Haider, Mintallah Al Ali, Najla H Lancet, Jeffrey E Epling-Burnette, Pearlie K List, Alan F Padron, Eric Komrokji, Rami S Producer: 20210531 In: Clinical lymphoma, myeloma & leukemia vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	14.	Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. [electronic resource] by Griffin, Patrick T Komrokji, Rami S Sweet, Kendra Al Ali, Najla H Padron, Eric Kubal, Timothy E List, Alan F Lancet, Jeffrey E Producer: 20170717 In: American journal of hematology vol. 92 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	15.	ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. [electronic resource] by Sallman, David A Komrokji, Rami Cluzeau, Thomas Vaupel, Christine Al Ali, Najla H Lancet, Jeffrey Hall, Jeff List, Alan Padron, Eric Song, Jinming Producer: 20180831 In: Blood cancer journal vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	16.	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. [electronic resource] by Melody, Megan Al Ali, Najla Zhang, Ling Ramadan, Hanadi Padron, Eric Sallman, David Sweet, Kendra Lancet, Jeffrey List, Alan Bennett, John M Komrokji, Rami Producer: 20210601 In: Clinical lymphoma, myeloma & leukemia vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	17.	Defining Acute Myeloid Leukemia Ontogeny in Older Patients. [electronic resource] by Melody, Megan Kuykendall, Andrew Sallman, David Al Ali, Najla Zhang, Ling Talati, Chetasi Padron, Eric Sweet, Kendra Extermann, Martine List, Alan Lancet, Jeffrey Komrokji, Rami Producer: 20210601 In: Clinical lymphoma, myeloma & leukemia vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	18.	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. [electronic resource] by Prebet, Thomas Toma, Andrea Cluzeau, Thomas Sekeres, Mikkael A Vey, Norbert Park, Sophie Al Ali, Najla Sugrue, Marie M Komrokji, Rami Fenaux, Pierre Gore, Steven D Producer: 20180424 In: Oncotarget vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	19.	Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. [electronic resource] by Jaglal, Michael V Duong, Vu H Bello, Celeste M Al Ali, Najla H Padron, Eric Fernandez, Hugo F List, Alan F Lancet, Jeffrey E Komrokji, Rami S Producer: 20140602 In: Leukemia research vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	20.	The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. [electronic resource] by Kuykendall, Andrew T Talati, Chetasi Al Ali, Najla Sweet, Kendra Padron, Eric Sallman, David A Lancet, Jeffrey E List, Alan F Zuckerman, Kenneth S Komrokji, Rami S Producer: 20180709 In: Clinical lymphoma, myeloma & leukemia vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

1
2
3
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 46 results.